Chemotherapy-induced scleroderma: A pleiomorphic syndrome

Clinical and Experimental Dermatology

Volumn 30, Issue 2, 2005, Pages 141-145

  Alexandrescu, D T ^a   Bhagwati, N S ^a   Wiernik, P H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PENICILLAMINE; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HUMAN; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; SCLERODERMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ERUPTIONS; FEMALE; HUMANS; MIDDLE AGED; SCLERODERMA, DIFFUSE;

EID: 15244360524     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01668.x     Document Type: Article

References (17)

1. Cleveland MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by docetaxel: a case report. Cancer 2000; 88: 1078-81.
2. Battafarano DF, Zimmerman GC, Older SA et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995; 76: 110-5.
3. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 2001; 19: 197-200.
4. Kupfer I, Balguerie X, Courville P et al. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. Am Acad Dermatol 2003; 4-8: 279-81.
5. Lauchli S, Trueb RM, Fehr M, Hafner J. Scleroderma-like drug reaction to paclitaxel (Taxol). Br J Dermatol 2002; 147: 619-21.
6. De Angelis R, Bugatti L, Cerioni A et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 2003; 22: 49-52.
7. Haviv YS, Dadafi R. Rapid progression of Scleroderma possibly Associated with Penicillamine. Ther Clin Drug Invest 1998; 15: 61-3.
8. Fraschini G, Arnett FC, Manning JT. Acute systemic sclerosis (scleroderma) that mimicked treatment-related complications in a breast cancer patient. Am J Clin Oncol 1988; 11: 77-83.
9. Emir S, Kutluk T, Topaloglu R et al. Scleroderma in a child after chemotherapy for cancer. Clin Exp Rheumatol 2001; 19: 221-3.
10. Korn JH. Overview of the manifestations and diagnosis of scleroderma. In: Burton, DR, Joseph, MR., eds. Uptodate Online 2003; 11: 3.
11. Gilliland B. Systemic Sclerosis (Scleroderma), In: Fauci, AS, Braunwald, E, Isselbacher, KJ et al., eds. Harrison's Principles of Internal Medicine, 14th edn. New York: McGraw-Hill 1998: 1888-96.
12. Tsavaris N, Kosmas C, Vadiaka M et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002; 87: 21-7.
13. Klaich GM, Kanter PM. Induction of dog IL-1 by free and liposomal encapsulated doxorubicin. Anticancer Drugs 1994; 5: 355-60.
14. Abdul Hamied TA, Parker D, Turk JL. Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int J Immunopharmacol 1987; 9: 355-61.
15. Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res 1986; 46: 4213-6.
16. Ujhazy P, Zaleskis G, Mihich E et al. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 2003; 52: 463-72.
17. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24: 663-5.